IGF1 and depressive symptom measurement: In an LPS model of depression, central administration of IGF-1 is shown to prevent LPS-induced sickness- and depression-like behavior (Park et al., 2011a,b) in association with an induction of BDNF and a reduction of TNF-α, IL-1β, and iNOS in the pre-frontal cortex (PFC; Park et al., 2011b).